Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE-PCP neoadjuvant dabrafenib plus trametinib in newly diagnosed papillary craniopharyngioma
ChiCTR2400081636Phase 2Recruiting
- Sponsor
- Huashan Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in Papillary craniopharyngioma (pCP), sponsored by Huashan Hospital. Primary endpoint: Objective response rate. Started Mar 2024; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Papillary craniopharyngioma (pCP)
Beyond the preview
Go deeper on ChiCTR2400081636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081636.